Characterization of bradykinin receptors in guinea pig gall bladder.

Specific binding of [3H]bradykinin (BK) to guinea pig gall bladder (GPGB) membranes was protein dependent, rapid (Kon = 0.067 min-1) with high affinity (Kd = 0.45 +/- 0.02; n = 3), saturable (Bmax = 546 +/- 56 fmol/mg of protein) and showed no cooperativity (nH = 1.19 +/- 0.08). A BK B2 receptor type was indicated by the rank order of potency for inhibition of binding by B2 antagonists, [(D)Arg-[Hyp3,Thi5,(D)Tic7-Oic8]-bradykinin (HOE140) > (D)Arg-[Hyp3,(D)HypE(transpropyl)7-Oic8]-bradykinin (NPC17731) > (D)Arg-[Hyp3,Thi5, (D)Tic7-Tic8]-bradykinin (NPC16731) > (D)Arg-[Hyp3,(D)Phe7]-bradykinin (NPC567)] and agonists (BK = kallidin = Tyr(Me)8-BK > Tyr8-BK,> Hyp4-kallidin) as well as inactivity of the B1 agonist des(Arg9)-BK. Nonhydrolyzable GTP analogs (GTP-gamma-S and guanylyl-5'-imido-diphosphate) produced 80% inhibition of specific binding suggesting receptor coupling to guanine nucleotide-binding proteins. BK increased polyphosphoinositide hydrolysis in chopped GPGB in a concentration-dependent manner (0.01-300 microM; EC50 = 414 +/- 171 nM; n = 3-9 tissues/concentration). HOE140 and NPC16731, inhibited BK-induced polyphosphoinositide hydrolysis but only the latter appeared competitive (pKb 8.09 +/- 0.19, n = 3). U73122, an inhibitor of phospholipase C pathway, also inhibited BK-induced turnover in GPGB (IC50 = 46.9 +/- 17.3 nM). BK produced a concentration-related contraction of isolated strips of GPGB. Indomethacin significantly decreased both the potency and efficacy of BK whereas thiorphan, a neutral endopeptidase inhibitor, and/or captopril, an angiotensin-converting enzyme inhibitor, enhanced potency.(ABSTRACT TRUNCATED AT 250 WORDS)

Guinea pig gall bladder contains a single peptide leukotriene receptor which resembles that present in human conducting airway smooth muscle.

The peptide leukotrienes (LTs), LTC4, LTD4 and LTE4, produced concentration-related contraction of isolated strips of guinea pig gall bladder (GPGB) with pD2 values of 8.48 +/- 0.11, 8.26 +/- 0.22 and 7.28 +/- 0.08, respectively. In the presence of propranolol and indomethacin in epithelium-denuded GPGB, pKB values for the LT antagonist ICI198,615 vs. LTC4, LTD4 and LTE4 were, respectively: 8.61 +/- 0.12, 8.89 +/- 0.13 and 8.70 +/- 0.17. Similarly, pKB values for the LT antagonist SKF104,353 were 7.28 +/- 0.19, 7.88 +/- 0.17 and 7.45 +/- 0.17. Previous studies have shown that inhibition of LTC4 metabolism can alter the apparent affinity of the LT, especially LTC4; consequently, metabolism of [3H]LTC4 in chopped GPGB was investigated. [3H]LTC4 was converted rapidly by gamma-glutamyl transpeptidase to [3H]LTD4 with little accumulation of [3H]LTE4. The combination of acivicin (ACI) and reduced glutathione (GSH) provided complete inhibition of gamma-glutamyl transpeptidase. pD2 values for LTC4 in the presence of ACI/GSH were 8.54 +/- 0.16. pKB values for ICI198,615 and SKF104353 in the presence of ACI/GSH were, i.e., 8.42 +/- 0.14 and 7.53 +/- 0.12, respectively, vs. LTC4 and identical to those obtained in the absence of inhibitors. The mechanism(s) underlying LT-induced contraction was evaluated using the calcium channel blockers diltiazem, nifedipine and verapamil. Noncompetitive antagonism was observed against all LTs indicating the involvement of voltage-sensitive calcium channels in the contractile response. Similarly, all LTs increased polyphosphoinositide hydrolysis. These data indicate: 1) GPGB contains a single type of LT receptor similar to that in human airways and 2) LT-induced contraction appears to involve both polyphosphoinositol formation and voltage-dependent Ca++ channels.

Leukotriene D4 increases both the force of contraction and polyphosphoinositide formation in guinea-pig papillary muscle.

Leukotriene D4 (LTD4) increased the force of contraction in guinea-pig papillary muscle. A rapid (less than 1 min), transient (less than 5 min) response to LTD4 (1 microM) reached 19.3 +/- 5.4% of isoproterenol maximum. A single exposure to LTD4 resulted in complete and homologous desensitization which was not influenced by indomethacin. LTD4 (0.1-3.0 microM) increased total inositol phosphates released from [3H]inositol-labeled tissue. ICI 198,615, a selective LT receptor antagonist, blocked both the increase in force of contraction and the increase in inositol phosphates by LTD4, but had no effect on the inotropic response to isoproterenol. These data support the existence of specific functional LTD4 receptors in myocardial tissue of guinea-pigs.

Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase.

ICI 200,880 and its close structural analog, ICI 200,355, are representatives of a new chemical class of inhibitors of human neutrophil elastase (HNE). Both compounds are substituted tripeptide ketones, which demonstrated competitive kinetics versus HNE, with identical Ki values of 5.0 x 10(-10) M. The selectivity of ICI 200,880 for HNE versus a variety of enzymes ranged from 150-fold [relative to porcine pancreatic elastase (PPE)] to greater than 360,000-fold in favor of HNE. The compound effectively inhibited HNE-hydrolysis of bovine ligamentum nuchae elastin. In pharmacokinetic studies, ICI 200,880 and ICI 200,355 displayed long retention times when administered directly to the lung and were rapidly eliminated after intravenous administration. Pretreatment of hamsters with either inhibitor before intratracheal administration of HNE produced dose- and time-dependent inhibition of enzyme-induced increases in lung weight, total lavageable red cells, and total lavageable white cells. Aerosol administration of ICI 200,880 produced similar results. Subcutaneous administration of either 50 or 100 mumol/kg (twice/day) of ICI 200,880 for 14 or 28 days prevented the time-dependent increase in alveolar diameter produced by a single intratracheal dose of PPE when compound dosing was initiated 24 h after the enzyme. Treatment of hamsters with the same protocol and doses of ICI 200,880 for 8 wk prevented the destructive lesion induced by a single intratracheal dose of HNE. It is concluded that ICI 200,880 and ICI 200,355 have biochemical, pharmacokinetic, and pharmacologic profiles that make them useful therapeutic agents for understanding the role of HNE in various diseases. ICI 200,880 is presently being evaluated in humans.

Evidence for leukotriene D4 receptors in guinea pig left atria.

The effects of peptidoleukotrienes (LTs) on electrically driven guinea pig left atria (GPLA) were investigated. LTD4 produced a positive inotropic response; however, rapid desensitization required the construction of noncumulative dose-response curves to naive tissues. The maximal inotropic response to LTD4 was 24 +/- 3% of isoproterenol and the EC50 = 267 +/- 77 nM. The functional response was corroborated by the demonstration of specific and rapid [3H]LTD4 binding to GPLA membranes with low affinity (Kd = 212 +/- 80.2 nM), in a saturable (Bmax = 20 +/- 1.1 pmol/mg protein) manner. In tissues pretreated with acivicin, which inhibits conversion of LTC4 to LTD4, the response to LTC4, but not LTD4, was abolished. Selectivity towards LTD4 was demonstrated by the inability of propranolol, prazosin, atropine, pyrilamine, capsaicin or indomethacin (all tested at 1 microM) to alter the functional response to LTD4. Similarly, none of the tested compounds (100 microMs) was inhibitory in the binding assay. Structurally diverse LTD4 antagonists SKF102922 (pKb = 6.42) and ICI 198.615 (pKb = 8.74) were able to inhibit the functional response as well as [3H]LTD4 binding to GPLA membranes. The calcium channel antagonist, verapamil, inhibited the functional response but did not alter [3H]LTD4 binding. These data support the existence of specific LTD4 receptors in GPLA which evoke a modest, rapidly desensitized, increase in the force of myocardial contraction.

Modulation of affinity and density of LTB4 receptors on guinea pig lung membranes by divalent cations and guanine nucleotides.

We investigated the mechanism by which guanine nucleotides and divalent cations modulate the affinity and apparent density of high-affinity receptors for Leukotriene B4 (LTB4) on guinea pig lung membranes (GPLM). Divalent cations (Mg2+ = Ca2+ greater than Mn2+) stimulated, whereas EDTA inhibited (IC50 = 0.31 +/- 0.08 mM) binding of [3H]LTB4. Saturation analysis demonstrated that omission of divalent cations caused a two-fold reduction in apparent site density, (B max = 297 +/- 24 fmol/mg protein vs. 149 +/- 21 fmol/mg protein, P less than 0.01, for control and EDTA-treated respectively), but no significant change in receptor affinity (KD = 0.67 +/- 0.16 nM and 1.01 +/- 0.19 nM, P greater than 0.05). Competition experiments with LTB4 and the low-affinity (Ki = 165 nM) competitive LTB4-antagonist U75302, also demonstrated that EDTA caused a significant reduction (1.7 and 3.6-fold, P less than 0.05 and P less than 0.01, respectively), in affinity to both ligands. In the same experiments, the the guanine nucleotide analog GppNHp also reduced the affinity for LTB4 and U75302, similar to that observed with EDTA, suggesting that removal (Mg2+), or addition (GppNHp), of allosteric modulators of G-protein(s), causes reduction in receptor affinity. Saturation experiments also demonstrated that GppNHp, or GTP(gamma S), caused a significant reduction (40-50%) in receptor density. A larger reduction in affinity for U75302 (3- to 3.6-fold) than for LTB4 (1.7-fold) was induced by EDTA as well as GTP analogs.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute blood pressure effects of selected serine proteases in normotensive rats and dogs.

The effects of bolus intravenous injections of various serine proteases (thrombin, trypsin, plasmin, neutrophil elastase and chymotrypsin) on arterial blood pressure were evaluated in anesthetized, normotensive rats. The activity to intravenous trypsin was also studied in anesthetized, normotensive dogs. In the rat, both thrombin (0.33-10 nmol/kg) and trypsin (4.2-420 nmol/kg) produced pronounced vasodepressor responses. The activity on blood pressure was observed immediately following injection of either protease, and both the magnitude and duration of the responses were dose dependent. Plasmin (37-350 nmol/kg) and neutrophil elastase (91-910 nmol/kg) also induced dose-dependent hypotension but at much higher dose levels. In addition, the magnitude of the blood pressure responses after plasmin and neutrophil elastase was less than those produced by thrombin and trypsin. Chymotrypsin, on the other hand, had a more diverse blood pressure profile. The protease induced a modest decrease in pressure at doses of 40 and 120 nmol/kg, a pressor response after 400 and 1,200 nmol/kg and at the highest dose tested (4,000 nmol/kg) profound hypotension. In the dog, trypsin produced a dose-dependent vasodepressor response similar to that observed in the rat. The doses of proteases producing alterations of blood pressure in the rat correlated inversely with the ability of rat serum or plasma to completely inhibit those proteases. The pharmacology of the trypsin or thrombin blood pressure response suggests the requirement of specific active enzymes to mediate the vasodepression induced by both proteases.

Modulation of ligand binding to leukotriene B4 receptors on guinea pig lung membranes by sulfhydryl modifying reagents.

We investigated the mechanism and modulation of 3H-labeled leukotriene B4 (LTB4) binding to guinea pig lung membranes. [3H] LTB4 bound specifically and rapidly (Kobs = 0.06 +/- 0.006 min-1) to high affinity (Kd = 0.63 +/- 0.06 nM) and saturable (Bmax = 224 +/- 16 fmol/mg) sites without cooperativity (nH = 1.05). Bound ligand was partially (70%) dissociated with excess LTB4 or the selective antagonist U-75,302. Complete dissociation could be achieved with either LTB4 or U-75,302 in combination with 10 microM GTP gamma S. A series of structural analogs and selective antagonists inhibited binding in a competitive manner with the following order: LTB4 much greater than 20-(OH)-LTB4 greater than LTB5 greater than LTB-dimethylamide = U-75,302 greater than 12(R)-hydroxy-eicosatetraenoic acid greater than 5(S),12(S)-dihydroxy,6-trans,8-cis,10-trans,14-cis-ETE greater than 12(S)-hydroxy-eicosatetraenoic acid much greater than trans-LTB4 isomers. 5(S)-hydroxy-eicosatetraenoic acid, prostaglandins, peptide-leukotrienes and platelet-activating factor (at 10 microM each) did not inhibit, providing evidence that [3H]LTB4 bound to specific receptors on guinea pig lung membranes. N-Ethylmaleimide (NEM) and p-chloromercuriphenyl sulfonic acid (PCMP) inhibited binding (IC50 = 144 +/- 66 and 4.6 +/- 1.0 microM, respectively) in an irreversible manner, as evident by an inability to overcome the inhibition by extensive washing.(ABSTRACT TRUNCATED AT 250 WORDS)

Specific binding of 3H-ICI 198,615, a potent LTD4 antagonist, to guinea pig cardiac ventricular membranes.

Peptido-leukotrienes (LTs) elicit myocardial depression in several mammalian species, and radioligand binding assays with 3H-LTC4 and 3H-LTD4 have provided evidence of putative receptor sites on guinea pig cardiac ventricular membranes (GPCVM). Our objective was to characterize specific binding of 3H-ICI 198,615, a potent and selective LTD4 antagonist, to the 155,000 X g pellet of GPCVM. 3H-ICI 198,615 (0.01-3.8 nM) showed high specific binding (85-90% of total), which was protein dependent, saturable (Bmax = 4914 +/- 706 fmol/mg protein, n = 3), of high affinity (Kd = 4.3 +/- 0.8 nM, n = 3) and without cooperativity. Equilibrium binding was achieved by 20 minutes and could be rapidly reversed by addition of excess unlabeled ICI 198,615 or FPL55712. Competition studies with 3H-ICI 198,615 against several LTD4 antagonists produced an order of potency: ICI 198,615 much greater than SKF102922 greater than FPL55712 greater than or equal to LY171883. Addition of divalent cations caused a concentration dependent decrease in specific binding apparently due to a reduction in affinity. Binding was not influenced by the guanine nucleotide analogs GTP gamma S and Gpp(NH)p, EDTA, or a multitude of diverse non-LT receptor agonists and antagonists. These data provide evidence supporting the existence of specific and high affinity binding sites for 3H-ICI 198,615 in GPCVM.

Guanyl-5'-yl-lmidodiphosphate regulation of ligand binding to LTD4 receptors on guinea pig lung membranes.

We investigated the mechanism of guanyl-5'-yl-imidodiphosphate (GppNHp) regulation of peptidoleukotrienes (LTs) and LT-antagonists binding to LTD4 receptors on guinea pig lung membranes (GPLMs). In saturation experiments, [3H]LTD4 saturable (maximum binding = 943 +/- 39 fmol/mg of protein) binding to GPLM was significantly (P less than .01) inhibited by GppNHp (60 nM, maximum binding = 446 +/- 113 fmol/mg of protein) in a concentration-dependent manner. No significant change in the affinity (Kd = 0.29 +/- 0.02 nM vs. 0.43 +/- 0.12 nM for control and treated GPLM, respectively) for [3H]LTD4 was observed. The binding affinity for the selective LTD4 antagonist ICI 198,615 (Ki = 0.13 +/- 0.04 nM) as determined by competition against [3H]LTD4, was not changed by GppNHp. Saturation analysis of [3H]ICI 198,615 binding confirmed that GppNHp did not change the apparent affinity or site-density for this ligand. In competition experiments against [3H]-ICI 198,615, GppNHp (1 microM) caused a significant (P less than .01) rightward shift of the inhibition by agonists (94-, 50- and 8-fold shifts for LTD4, LTE4 and YM-17690, respectively). In contrast, inhibition of [3H]ICI 198,615 by four LTD4 antagonists (ICI 198,615, 4-[5-cyclopentylcarbonylamino-1-[3-cyanobenzyl] indol-3-yl-methyl]3-methoxybenzoic acid, 4-[5-cyclopentylcarbonylamino-3-chloroindol-1-y-methyl]3-met hoxybenzoic acid and FPL55712) was not affected by GppNHp. Taken together the data suggest that LTD4 receptors are coupled to a G-protein that modulates the affinity of agonists but not antagonists binding.

Kinetic and pharmacologic analysis of [3H]leukotriene E4 binding to receptors on guinea pig lung membranes: evidence for selective binding to a subset of leukotriene D4 receptors.

The specific binding of [3H]leukotriene (LT) E4 to receptors on guinea pig lung parenchymal membranes was investigated and compared to that of [3H]LTD4. [3H]LTE4 bound slower than [3H] LTD4 (k1: 0.07 +/- 0.02 nM-1.min-1 vs. 0.13 +/- 0.01 nM-1.min-1, respectively) reaching equilibrium at lower binding levels (3-fold) than [3H]LTD4. Unlike [3H]LTD4, receptor-bound [3H]LTE4 could be rapidly (k-1 = 0.22 +/- 0.04 min-1) and fully dissociated by excess of both agonists (LTD4 and LTE4) and selective LTD4/LTE4 antagonist ICI 198,615. Equilibrium saturation analysis (paired) of specific [3H]LTE4 and [3H]LTD4 binding confirmed that [3H]LTE4 possesses lower affinity (kd values: 1.17 +/- 0.14 and 0.38 +/- 0.06 nM, respectively, n = 6, P less than .01) and lower density (maximum binding values: 524 +/- 46 and 988 +/- 66 fmol/mg, n = 6, P less than .01) binding sites. Binding of [3H]LTE4 was 3 to 4-fold more sensitive to inhibition by GTP analogs than has been demonstrated previously on [3H]LTD4. Drug competition assays illustrate that inhibition of [3H]LTE4 binding by agonists displays similar selectivity of (LTD4 greater than LTE4 much greater than LTC4) and stereoselectivity (5S,6R-LTD4 much greater than R,R greater than R,S greater than S,S) to the observed inhibition of [3H]LTD4, suggesting that [3H]LTE4 binds to LTD4 receptors. Selective LTD4 antagonists inhibited [3H]LTE4 binding with a relative potency [compound 1 (ICI 198,615 analog) greater than ICI 198,615 = ICI 204,219 greater than LTD4 greater than LTE4 much greater than FPL55712 = LY171,883] comparable to that obtained against [3H]LTD4.(ABSTRACT TRUNCATED AT 250 WORDS)

Inhibition of 3H-leukotriene D4 binding to guinea pig lung receptors by the novel leukotriene antagonist ICI 198,615.

The specific binding of [3H]5(S)hydroxy-6(R)-S-cysteinylglycyl -7(E),9(E),11(Z),14(Z)-eicosatetraenoic acid ([3H]LTD4) to receptors on guinea pig lung parenchymal membranes and its inhibition by ICI 198,615, a representative example of a new class of leukotriene antagonists, was characterized by a receptor-ligand binding assay. [3H]LTD4 bound specifically and rapidly (Kon = 0.29 +/- 0.6 nM-1.min-1) reaching equilibrium within 15 min. The rate of binding was greatly inhibited in the presence of ICI 198,615. Excess LTD4 or ICI 198,615 slowly (t1/2 = 20 min) dissociated about 70% of the receptor-bound [3H]LTD4, whereas in combination with GTP analogs, both induced a rapid (t1/2 less than 5 min) and full dissociation. Equilibrium saturation analysis of [3H]LTD4 binding demonstrated a saturable (Bmax = 1014 +/- 174 fmol/mg) and high affinity (Kd = 0.43 +/- 0.09 nM) binding site. A high degree of stereoselectivity was demonstrated with inhibition of binding by the stereoisomers of LTD4: S,R much greater than R,R greater than R,S much greater than S,S. The rank order for inhibition of binding by peptide leukotriene was: LTD4 greater than 5(S)-hydroxy-6(R)-S-cysteinyl-7(E),9(E),11(Z),14(Z)-eicosatetraenoic acid much greater than 5(S)hydroxy-6(R)-S-glutathionyl-7(E),9(E),11(Z),14(Z)-eicosatetraenoic acid (potency ratios were: 1:4:590). In competition assays, ICI 198,615 competitively inhibited binding of [3H]LTD4 (Ki = 0.27 +/- 0.16 nM) and was 2300-fold and 3100-fold more potent than LY171883 or FPL55712. These data, together with results obtained previously in functional receptor assays, illustrate that this new class of leukotriene antagonists are the most potent and selective competitive antagonists of LTD4 receptors yet described.